Evotec loses science chief. Evotec stock falls 1.28 percent

Published on 10/01/2026 at 13:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cord Dohrmann exits after 16 years in the role. Evotec stock costs EUR 3.08 on October 1, 2026 after EUR 3.12, minus 1.28 percent.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) was trading at EUR 3.08 at Lang & Schwarz on October 1, 2026 at 1:05 p.m. CEST, down 1.28 percent versus the prior close of EUR 3.12. The company announced on September 29, 2026 that Chief Scientific Officer Cord Dohrmann would leave effective September 30 after 16 years in the role, according to PR Newswire.

Leadership changes after weak results

Dohrmann has served as Evotec's Chief Scientific Officer and a member of its Management Board since 2010. The company said the search for a successor is ongoing, making research leadership the latest point of change as management works through a difficult operating year.

Evotec's first-half 2026 revenue fell 19.2 percent year over year to EUR 300.1 million, while adjusted EBITDA deteriorated to a loss of EUR 42.7 million from a loss of EUR 1.9 million in the first half of 2025, Stock-World reported on September 7, 2026.

Guidance remains the central test

For fiscal year 2026, Evotec guides to revenue of EUR 570 million to EUR 610 million and an adjusted EBITDA loss of EUR 70 million to EUR 105 million. The ranges compare with earlier guidance of EUR 700 million to EUR 780 million in revenue and adjusted EBITDA of EUR 0 million to EUR 40 million, according to Borse Express on September 10, 2026.

The operating picture is mixed within the group. Discovery and Preclinical Development revenue rose 28 percent in the first half of 2026, but that increase did not offset the group revenue decline, leaving the lower guidance as the main benchmark for upcoming results.

Analyst target stays above the quote

Berenberg maintained its Hold rating and a EUR 3.60 price target after a discussion with Chief Executive Officer Christian Wojczewski. The note was dated September 24, 2026, and was reported by Ariva on September 25, 2026. The target is EUR 0.52 above the Lang & Schwarz quote, but the comparison uses different reference dates and is not a forecast from this article.

Third-quarter date sets the next checkpoint

Evotec is scheduled to publish its final third-quarter 2026 figures on November 5, 2026, according to Borse Express. That report will put revenue conversion, adjusted EBITDA and progress under the Horizon savings program against the reduced full-year ranges.

Evotec stock trades below EUR 3.10

Evotec was trading at EUR 3.08 at Lang & Schwarz on October 1, 2026 at 1:05 p.m. CEST, down 1.28 percent from the EUR 3.12 prior close. The stock is listed in the Frankfurt Prime Standard under ticker EVT, while the company release also identifies its Nasdaq symbol as EVO. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.